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Abstract
In the last decade, many researches have reached to the conclusion that preservation of residual renal function 
(RRF) is important after initiating dialysis, as well as in the predialysis period. 
RRF has  been proven to contribue to the quality of life  of dialysis  patients.  Longer preservation  of RRF 
provides a better small and middle molecule removal, improved volemic status and arterial pressure control, diminished 
risk of vascular and valvular calcification due to better phosphate removal. Deterioration of RRF results in worsening of 
anemia, inflammation and  malnutrition. It is now proven  a direct  relationship between RRF value and  survival  in 
dialysis patient.
Several therapeutical intervention have been proven to ameliorate the decline of RRF in dialysis patients. Some of them 
are identical with those before initiating dialysis: ACE-inhibitors and/or angiotensin-receptor blockers, limiting the use 
of nephrotoxic drugs, avoiding contrast media procedures, adequate control of blood pressure. Others are specific for 
dialysis period: adequate dialysis dose, avoiding excessive ultrafiltration, preventing arterial hypotension during dialysis 
sessions, using biocompatible dialysis membranes, ultrapure water for dialysis, dietary interventions.
Measurement of RRF
The exact value of RRF is necessary both 
at the moment of initiating dialysis therapy and on 
the  course  of  the  dialytic  therapy  in  order  to 
adjust, simultaneous with the RRF decrease, the 
dose of dialysis. 
The  value  of  remaining  diuresis  do  nor 
correlate with RRF [1]. 
The  inuline  clearance  is  the  standard 
method  to  which  other  GFR  measurements  are 
compared, but it is expensive, especially when it 
has to be repetead at regular intervals during the 
dialytic therapy [2]. 
The  creatinine  clearance  is  frequently 
used in current practice for GFR estimation, but it 
has limits: the creatinine depends not only on the 
glomerular filtration rate, but also on the muscular 
mass  and  individual’s  age;  within  the  kidney, 
besides  free  glomerular  filtration,  creatinine 
suffers  tubular  secretion  too,  which  becomes 
significant  as  the  renal  function  deteriorates;  in 
uremics,  creatinine  extrarenal  (intestinal) 
elimination is present too. In addition, the usual 
method  of  measuring plasma  creatinine  (with 
alkaline picrat) may give results that are falsely 
higher because of the non-creatinine cromogens. 
As a result, creatinine clearance, calculated by the 
classical formula UxV/P, overestimates the GFR 
real value [2].
The blood urea or urea clearance are even less 
precise for GFR estimation. The production of 
urea depends on diet, proteic catabolism, and 
the excretion is influenced by diuresis. Within 
the  kidney,  urea,  after  glomerular  filtration, 
suffers  tubular  reabsorption.  Urea  clearance 
underestimates the real value of GFR.
Cockcroft  and  Gault  formula  for 
creatinine clearance has been developed in order 
to  exceed  the  limits  of  the  classical  formula 
(UxV/P), but this formula allows a prediction only 
for the endogene creatinine, not for the GFR [3,4]. 
The inhibiton of the creatinine  tubular secretion 
with cimetidine may provide assessments close to 
the  real  ones,  but  the  necessary  doses  are  very 
high  and  there  can’t  be  achieved  a  complete 
blocking  of  tubular  secretion.  In  addition,  for 
hemodialysed  patients,  the  blocking  of  tubular 
secretion of  creatinine by cimetidine  won’t take 
effect [3].
MDRD formula (modification of diet in renal 
disease) is not usefull in estimating RRF in 
dialysed patients, because it overestimates the 
real values, sometimes with 100% [5].
Clearance of β2 microglobulin or cistatine 
may represent an alternative of RRF estimation, 
because  they  are  excreted  only  by  glomerular Journal of Medicine and Life  Vol. 2, No.2, April-June 2009 
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filtration, but their use in dialysed patients hasn’t 
come into the current use yet [6]. 
GFR  isotopic  markers  –
125I-iothalamate, 
99mTc-DTPA  or 
51Cr-EDTA  – have  the 
advantage  of  simplicity  and  avoid  urine 
collection, but may overestimate real GFR as 
they  are eliminated  by  extrarenal routes too 
and  have  a  large  volume  of  distribution; 
besides,  they  are  expensive  [7].  The 
overestimation of real GFR, by approximately 
20% in patients  with normal  renal  function, 
increases  as  the  renal  function  deteriorates. 
Iohexol clearance represents a method of GFR 
value  estimation  without  a  risk  of  affecting 
the remaining kidney function, but it is also 
expensive [8].
Numerous  studies  show  a  good 
correlation  between  the  arithmetic  mean  of 
creatinine and urea clearance and RRF real value 
[7];  clearances  are  calculated  by  the  classical 
formula (UxV/P). This method is cheap and easy 
to repeat, depending only on patient’s compliance. 
For  HD  patients,  plasma  values  for  urea  and 
creatinine are measured one of the days between 
the dialysis sessions, when urine is collected for 
24 hours.
RRF  and  mortality  risk  in  dialysis 
patients
Several  researches demonstrated  that 
preservation of RRF is associated with better 
survival rate, both in PD and HD patients. 
The first research emphasizing that RRF 
has an influence on survival of PD patients was 
performed in 1995 by Maiorca [9], who studied 
RRF as an independent factor, demonstrating that 
the persistence of a significant renal clearance is 
accompanied by a longer survival in PD patients. 
Subsequent studies [10,11,12] revealed that RRF 
and not the dialysis dose is predictive for a longer 
survival of PD patients. CANUSA study (Canada-
USA  Peritoneal  Dialysis  Study  Group),  whose 
results  were  published  in  1996  [13]  and  which 
started  with  the  premise  of  an  equivalence 
between  RRF  and  PD  clearance,  demonstrated 
that the sum of the two clearances (RRF + PD) for 
small molecules is a predictor irrespective of other 
factors  for  the  mortality  of  PD  patients. 
Reanalysis [14] of the data of CANUSA study in 
2001  showed  that  RRF  and  not  the  dose  of 
dialysis is the one that directly influences patients’ 
survival.
Other researches [15,16] demonstrated the 
same relation between RRF and survival rate in 
HD patients.
In  2002,  the  ADEMEX  (ADEMEX = 
ADEquacy  of  Peritoneal  Dialysis  in  MEXico) 
study, performed in PD patients, has reached to 
the  conclusion  that  residual  renal  clearance  and 
the  dialytic  clearance  are  not  equivalent  and 
additive [17]. Increasing solvite clearance in DP 
was not accompanied with better survival rate in 
overall or anuric patients, demonstrating that RRF 
was  the  one  that  directly  influenced  patients’ 
survival  rate.  This  observation  led  to  the 
conclusion  that  preserving  RRF  has  additional 
metabolic benefits, beyond better low molecular 
solvites removal. Indeed, subsequent studies [18] 
demonstrated  an increased frequency in anurics, 
compared  to  patients  with  preserved  RRF,  of 
numerous  metabolic  and  cardiovascular 
complications:  more  severe  anemia,  increased 
frequency  of  erythropoietin  resistance,  higher 
CaxP  product,  increased  rate  of  malnutrition, 
inflammation, and ventricular hypertrophy. 
Impact of RRF upon volemic status and cardiac 
hypertrophy
Extracellular liquid volume is increased in 
peritoneal  dialyzed  patients  with  residual  GFR 
below  2mL/min  than  in  patients  with  residual 
GFR  above  2mL/min  [19].  In  the  reanalyse  of 
CANUSA study [14], every 250mL of urine was 
associated with 36% reduction in global mortality 
for  PD  patients.  These  data  -indirectly-
emphasized  that  the  kidney,  even  in  advanced 
stages  of  functional  insufficiency,  has  a  major 
importance  in  eliminating  water  and  sodium. 
Subsequently,  the  study  done  by  Ates  and 
collaborators  [20]  confirmed  that  the  value  of 
sodium  and  water  fractional  excretion  has  a 
predictive value for the mortality of PD patients.
PD  patients  with  history  of  hidrosaline 
retention show  degrees  of  more  severe 
hypertrophy  and  cardiac  dilatation,  as  well  as 
more  important  alternation  both  of  systolic  and 
diastolic  function  than  in  the  patients  with 
controlled  volemia,  as  other  recent  studies 
demonstrate  [21,22].  Considering  that  cardiac 
hypertrophy  is  an  important  factor  of  mortality 
prediction for chronically dialysed population, the 
data  above  suggest  that  cardiovascular 
complications,  which  are  more  frequent  among 
anuric dialysed patients, are, at least partly, due to 
the inefficient control of volemia after RRF loss. 
In  PD  patients,  arterial  hypertension    is  more 
difficult to control as RRF decreases [22,23].
In addition, the same studies note that as 
RRF  decreases,  other  complications  appear;  the 
anemia  becomes  more  severe  (with  increased 
erythropoietin  needs),  hypoalbuminemia is 
aggravating, the arterial pressure pulse increases. 
All  those  data  suggest  that  RRF  influence  on 
cardiac hypertrophy is due not only to water and Journal of Medicine and Life  Vol. 2, No.2, April-June 2009 
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salt elimination, but also to other effects such as a 
better purification of uremic toxins. In predialysis
CRF patients, left ventricle (LV) mass increases 
parallel with the decrease in residual GFR [24]; 
initiating  PD  led  to  the  regression  of  left 
ventricular hypertrophy (LVH) and improvement 
of  the  cardiac  function  [25].  The  evidence  that 
residual renal clearance for solvents with low MW 
and  not  the  peritoneal  clearance  is  the  one  that 
directly influences LVH [22], as well as the fact 
that LVH regresses post-transplant [26] permitted 
the  observation  that  there  are  certain  non-
dialysing uremic toxins which mediates LVH in 
peritoneal dialysed patients.
There are a few studies [27,28] referring 
to RRF influence on volemia and cardiovascular 
status in HD patients. All demonstrate a directly 
proportional  relation  between  RRF  preservation 
and  the  control  of  volume–dependent 
hypertension and volemia.
RRF and calcium-phosphate balance
Most of the studies demonstrate a better 
phosphate control in PD versus HD [29,30] as a 
result of better removal of phosphate and better 
preservation of RRF. In PD patients the presence
of hyperphosphatemy is closely related with RRF 
rate: only 1/3 of the patients with preserved RRF 
show increased values of seric phosphates, while 
over  1/2  of  anurics  have  hyperphosphatemy. 
Anurics  also  have  an  increased  inflammatory 
status; the association of hyperphosphatemia and 
hypercalcemia  leads  to  the  increase  of  valvular 
calcification  risk,  vascular  wall  stiffening,  high 
degree of cardiac hypertrophy [30]. 
A study published by Wang and collab. in 2005 in 
Nephrology  Dialysis  Transplantation  [31] 
connects  valvular  calcification  predisposition  to 
fetuin-A  depletion,  a  circulatory  inhibitor  of 
calcification and a negative reactant of the acute 
stage. On the other hand, the authors did not find 
an  association  between  fetuin-A  depletion  and 
RRF reduction and they conclude that in anuric 
peritoneal dialysed patients, fetuin-A depletion is 
not  responsible  for  increased  frequency  of 
valvular calcification.
Inflammation and RRF
The  presence  of  inflammation  is  noted 
with  increased  frequency  (between  12-65%)  in 
chronic dialysed patients [32]. The inflammation 
degree, estimated by C-reactive protein [33,34] or 
interleukin-6  dosing  [35,36]  directly  influences 
dialysed patients’ survival rate and cardiovascular 
mortality.  In  predialysis  uremic  patients  it  was 
reported  an  inversely  proportional  relation 
between RRF  and  plasma  concentration  of  pro-
inflammatory mediators [40]. Similar results were 
published  in  PD  patients:  RRF  decrease  is 
associated  with  the  increase  of  inflammatory 
response  [39]  estimated  by  C-reactive  protein 
dosing [37] or by the sanguin level of a soluble 
vascular  cell  adhesion  molecule  [38].  All  the 
studies indicate that the relation between RRF and 
the  degree  of  inflammation  is  independent  of 
patient’s  cardiovascular  status  [41].  The 
mechanism through which RRF loss worsens the 
inflammation  of  chronically  dialysed  patients 
seems to be, as some studies on animals indicate, 
oxidative stress of vascular endothelium with the 
activation of monocytes and cytokines [42,43]. A 
vicious circle takes place: inflammation worsens, 
at  its  turn,  the  deterioration  of  RRF  [44].  The 
association of inflammation with LVH and RRF 
loss  has  an  additive  effect  on  cardiovascular 
complications rate in dialysed patients [39].
The  contribution  of  RRF  to  the 
nutritional status
Malnutrition  is  frequent  in  chronic 
dialysed  patients  and  represents  an  independent 
factor  which  influences  mortality,  especially  by 
cardiovascular  diseases.  The  preservation  of 
diuresis  and  implicitly  of  a  significant  RRF 
permits a more liberal hygieno-dietetic regimen. 
Using  systems  of  nutrition  estimation  that  are 
subjective  [45,46,47]  – questionnaires  on 
alimentary  supply,  good  condition,  etc  or 
objective  – dry  body  mass,  seric  albuminemia
[47,48],  most  of  the  studies  concluded  that  the 
proteic and energetic dietary amount, as well as 
the  vitamins  dietary  amount  are  inversely 
correlated  with  RRF  value.  Other  researches 
demonstrated a direct relation, independent of the 
dialysis  dose,  between  RRF  reduction  and  the 
appearance  of  malnutrition,  which  suggests  that 
native  kidney  removes  some  non-dialysable 
uremic toxins with medium MW.
RRF  loss  is  also  accompanied  by  a 
increased resting energy expenditure [49], which 
can  lead  to  malnutrition  unless  there  is  a 
compensatory  increase  in  energetic  and  proteic 
dietary regimen. The general and cardiovascular 
mortality risk correlates with increased basal energetic 
expenditure.  The  determinant  link  in  the  relation 
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cardiovascular mortality seems to be the loss of RRF; 
increasing the dialytic clearance has no benefits.
The importance of RRF in removal 
of uremic toxines
Preservation of a significant RRF allows a 
better  removal  of  uremic  toxins  with  medium 
molecular  weight.  Irrespective  of  the  dialysis 
type, β2 microglobulin level is lower in dialysed 
patients with preserved RRF [50,51,52]. In anuric 
PD  patients,  increasing  the  dialysis  dose  is 
followed by a better removal of toxins with low 
MW, but not of those with medium MW and other 
toxins that circulate bound to proteins – such as P-
cresol [53,54].
FRR and quality of life in dialysed 
patients
Considering all the factors that favorably 
influence  RRF  preservation  in  chronic  dialysed 
patients, one may conclude that the quality of life, 
not only the survival period is ameliorated. The 
patient  with  preserved  RRF  has  a  more  liberal 
diet,  a  better  compliance  to  potassium  and 
hidrosaline restrictions or to the drug regimens. A 
lower  rate  of  complications  needs  less  drugs, 
which  has  better  psychological  and  financial 
impact.  A  better  social  and  familial  insertion  is 
achieved,  the  sensation  of  handicap  which  is 
present  in  most  dialysed patients  due  to  the 
dependency  upon  extrarenal purification therapy 
is diminished or absent. Of course, there is a large 
individual variability which especially depends on 
patient’s  age  and  existing  co-morbidities;  the 
advanced  age,  the  coexistence  of  generalized 
manifestations  of  atherosclerosis,  predialitic 
cardiovascular diseases, etc are a few examples in 
which  the  RRF  influence  on  chronic  dialysed 
patient’s life is insignificant. 
NECOSAD  study  [55]  demonstrated,  in 
PD  patients,  a  positive  influence  of  RRF 
preservation  on  the  most  dimensions  of  life 
quality:  physical  functions,  vitality,  uremic 
symptoms, sleeping disorders; in the same study, 
the dialysis clearance had no influence on these 
dimensions.
Preservation of RRF in chronic dialysed 
patients
All the researches performed until present 
[56,57,58,59]  indicate  a  better  preservation  of 
RRF in PD versus HD, which gave birth to the 
concept of  <integrative care approach>  of CRF 
patient: patients with preserved RRF will initially 
be  oriented  to  PD  and,  after  losing  RRF, 
transferred on HD. 
A retrospective study performed in 2000 
on  a  large  number  of  patients  (“Van  BW, 
Vanholder RC, Veys Net al”. An evaluation of an 
integrative  care  approach  for  end-stage  renal 
disease  patients.  “J  Am  Soc  Nephrol 2000”) 
demonstrated that such an attitude is accompanied 
by a better survival rate in PD patients transferred 
on HD as compared to those that remained on PD 
or as compared to those who begun on HD from 
the beginning [60]. 
The superiority of PD in preserving RRF 
can be explained through two factors:
- Better hemodynamic stability in PD, 
which  decreases  renal  ischemic 
aggressions.  In  2000,  Moist 
demonstrated  that  higher  values  of 
postdialytic medium hypertension are 
associated  with  a  better  RRF 
preservation  in  chronic  HD  [59].  In 
NECOSAD  study  [55],  there  was 
demonstrated  a  relation  between  the 
frequency of intradialytic hypotension 
episods and the rate of RRF decline; 
the periods of volemic depletion were 
associated  with  a  more  rapid 
deterioration of RRF. 
- Nephrotoxic  effects  of  the  pro-
inflammatory  mediators  released 
within  the  extracorporeal  circuit of 
HD. 
On  the  other  hand,  recent  researches 
[61,62]  demonstrated  that,  using  biocompatible 
hemodialysis  membranes  and  ultrapure  water, 
RRF  decline  is  similar  to  the  one  in  the 
continuous  ambulatory  peritoneal  dialysis.  RRF 
decrease is more rapid in patients hemodialysed 
with cellulose membranes as compared to patients 
hemodialysed with high-flux polisulfone [63].
Foreign  substances  present  within 
incompatible  membranes, in contact with blood, 
stimulate mononuclear and complement activating 
[63].
Some  recent  studies  [64,65]  suggest  a 
more  rapid  deterioration  of  RRF  in  patients 
receiving  automatic  peritoneal  dialysis  (APD) 
versus those on continuous ambulatory peritoneal
dialysis  (CAPD)  and  explain  this  through  the 
intermittent nature of automatic peritoneal dialysis 
(APD)  which  produces  a  osmotic  and  volemic 
charge  less  steady  than  in  CAPD.  Other 
researches [59,66,67] consider these observations 
as  groundless  because  of  the  non-uniform 
selection of patients in ADP.Journal of Medicine and Life  Vol. 2, No.2, April-June 2009 
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Irrespective of the type of PD, the rate of 
RRF decline is correlated with the frequency of 
peritonitis  episodes  [44]  and  with  the  type  of 
dialysis solution.
Avoiding  nephrotoxic  drugs  - non-
steroidal anti-inflammatories, aminoglicosides etc 
– is not only a predialytic measure of preventing 
CRI progression, but it also must be done after the 
dialysis  initiation  in  order  to  preserve  RRF.  If 
investigations with contrast media are needed, all 
the  prophylactic  measures  must  be  taken  [68]: 
adequate  hydration  (eventually  HD  immediately 
after  the  procedure  for  adequate  ultrafiltration), 
the  minimum  necessary  dose,  prophylactic 
treatment  with  acetilcisteine  [69,70],  preferring 
hypo-osmolar non-ionic contrast substances [69]. 
In  PD  patients,  the  administration  of 
aminoglycosides is accompanied in some  of  the 
studies by an acceleration of RRF decline [71], 
while  in  other  studies  [72,73]  it  had  no 
influence, which is explainable through the
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